Patient P-01323

Synthetic patientNBL-101 · Day 110 · 55–64 · F · baseline S14Open companion preview

Therapy response

Stable

Tolerance

Deteriorating

GI state

Improving

Inflammatory state

Stable

Nutritional resilience

Improving

Discontinuation risk

54%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 GI symptom burden −12% vs expected — Dietary Support Protocol NP-02
Day 46 SC-12 recommended — Supportive Compound SC-12
Day 47 Patient accepted — Started SC-12 in the companion
Day 48 Tolerance state changed — Unstable → Improving
Day 52 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 53 GI symptom burden −14% vs expected — Supportive Compound SC-12
Day 59 Tolerance state changed — Unstable → Improving
Day 60 GI-04 recommended — GI Support Protocol GI-04
Day 61 Patient accepted — Started GI-04 in the companion
Day 69 GI symptom burden −27% vs expected — GI Support Protocol GI-04
Day 75 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 52.

Primary contributors, last 14 days

GI instability-9
Toxicity+7
Nutritional resilience+4

What helped?

Dietary Support Protocol NP-02Day 31
Result: symptom burden −12%
Supportive Compound SC-12Day 46
Result: symptom burden −14%
GI Support Protocol GI-04Day 60
Result: symptom burden −27%

LIFE OS recommendation

Monitoring Escalation ME-01

72%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 41
- WearableHRV 27 ms, trending down
Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
Autonomic recovery ↓45
- WearableResting HR 83 bpm
- WearableShort sleep window
Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
Drug metabolism and exposure ↑20
- BloodToxicity index 43

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 3 · butyrate capacity 47/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 26 ms
Sleep: 6.5 h
Steps: 7,641
Resting HR: 80 bpm

Daily log: GI score 36, nutritional resilience 51, adherence 59.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Log the daily check-in; one line is enough
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
No additional supplements this week
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01518	55%	S14	GI-04	improved	40
P-01473	53%	S14	GI-04	improved	51
P-01574	53%	S14	GI-04	improved	47
P-01627	52%	S14	GI-04	improved	54
P-01431	51%	S14	GI-04	improved	41
P-01501	51%	S14	GI-04	improved	45
P-01330	50%	S14	GI-04	improved	47
P-01649	50%	S14	GI-04	improved	46
P-01365	49%	S14	SC-12	improved	49
P-01624	49%	S14	GI-04	improved	52
P-01706	49%	S14	GI-04	improved	55
P-01534	48%	S14	GI-04	improved	50